cytopathic
mechanisms
dose-limiting
cumulative
irreversible cardiomyopathy
doxorubicin
evidence
oxidative stress
mitochondrial dysfunction
factors
pathogenic process
investigation
hypothesis
carvedilol
nonselective beta-adrenergic receptor antagonist
antioxidant
properties
cardiac
hepatic
mitochondrial
associated with
subchronic
doxorubicin
toxicity
Heart
liver
mitochondria
isolated
rats
treated
weeks
doxorubicin
carvedilol
combination
drugs
Heart mitochondria
isolated
doxorubicin-treated rats
depressed rates
state 3
respiration
O/min/mg protein
lower
respiratory control ratio
RCR
cardiac mitochondria
isolated
saline-treated
rats
Mitochondrial calcium-loading capacity
activity
NADH-dehydrogenase
suppressed
cardiac mitochondria
doxorubicin-treated rats
Doxorubicin
treatment
decrease
RCR
liver mitochondria
control
rats
inhibition
hepatic cytochrome oxidase activity
Coadministration
carvedilol
decreased
cellular vacuolization
cardiac
myocytes
prevented
inhibitory
effect
doxorubicin
mitochondrial
heart
liver
Carvedilol
decrease
mitochondrial
loading
inhibition
respiratory complexes
heart mitochondria
doxorubicin
Carvedilol
parameters
measured
heart
liver mitochondria
protection
carvedilol
structural
functional
cardiac tissue
damage
clinical
dose-limiting mitochondrial dysfunction
cardiomyopathy
long-term
doxorubicin
therapy
cancer
patients
